ATE551335T1 - Indolylmaleimid-derivate - Google Patents
Indolylmaleimid-derivateInfo
- Publication number
- ATE551335T1 ATE551335T1 AT09004073T AT09004073T ATE551335T1 AT E551335 T1 ATE551335 T1 AT E551335T1 AT 09004073 T AT09004073 T AT 09004073T AT 09004073 T AT09004073 T AT 09004073T AT E551335 T1 ATE551335 T1 AT E551335T1
- Authority
- AT
- Austria
- Prior art keywords
- indolylmaleimide derivatives
- indolylmaleimide
- derivatives
- gsk
- pkc
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0303319.8A GB0303319D0 (en) | 2003-02-13 | 2003-02-13 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE551335T1 true ATE551335T1 (de) | 2012-04-15 |
Family
ID=9952961
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04710393T ATE463491T1 (de) | 2003-02-13 | 2004-02-12 | Indolylmaleimid derivate |
| AT09004073T ATE551335T1 (de) | 2003-02-13 | 2004-02-12 | Indolylmaleimid-derivate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04710393T ATE463491T1 (de) | 2003-02-13 | 2004-02-12 | Indolylmaleimid derivate |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7820672B2 (de) |
| EP (2) | EP1597250B8 (de) |
| JP (2) | JP2006515004A (de) |
| CN (1) | CN100439359C (de) |
| AT (2) | ATE463491T1 (de) |
| BR (1) | BRPI0407512A (de) |
| CA (1) | CA2513613A1 (de) |
| DE (1) | DE602004026415D1 (de) |
| ES (2) | ES2343115T3 (de) |
| GB (1) | GB0303319D0 (de) |
| PT (1) | PT1597250E (de) |
| WO (1) | WO2004072062A2 (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2611607A1 (en) * | 2005-07-11 | 2007-01-18 | Novartis Ag | Indolylmaleimide derivatives |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| AU2007336338A1 (en) | 2006-12-19 | 2008-06-26 | Novartis Ag | Indolylmaleimide derivatives as kinase inhibitors |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| CN101671329B (zh) * | 2009-06-17 | 2012-11-07 | 东华大学 | 3-氨基醇取代的吲哚马来酰亚胺化合物、其制备和应用 |
| US9724331B2 (en) | 2012-12-10 | 2017-08-08 | Centogene Ag | Use of maleimide derivatives for preventing and treating leukemia |
| CN104693198B (zh) * | 2014-12-13 | 2017-03-08 | 浙江工业大学 | 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用 |
| KR20180015650A (ko) | 2015-05-07 | 2018-02-13 | 아게누스 인코포레이티드 | 항-ox40 항체 및 이의 사용 방법 |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| WO2018132636A1 (en) * | 2017-01-12 | 2018-07-19 | The Research Foundation For The State University Of New York | [18f]maleimide-based glycogen synthase kinase-3beta ligands for positron emission tomography imaging and radiosynthesis method |
| CN110551103B (zh) * | 2018-05-30 | 2022-08-23 | 北京大学深圳研究生院 | 一种jak3选择性抑制剂 |
| US20220133740A1 (en) | 2019-02-08 | 2022-05-05 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0629947B2 (ja) | 1986-07-16 | 1994-04-20 | 正浩 入江 | 光学記録材料 |
| CZ280738B6 (cs) * | 1988-02-10 | 1996-04-17 | F. Hoffmann - La Roche And Co., Aktiengesellschaft | Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi |
| DE4005970A1 (de) | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
| GB9123396D0 (en) | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
| AU3761393A (en) | 1992-03-20 | 1993-10-21 | Wellcome Foundation Limited, The | Indole derivatives with antiviral activity |
| JPH06161024A (ja) | 1992-11-26 | 1994-06-07 | Sanyo Electric Co Ltd | 光学記録材料 |
| US5405864A (en) | 1993-10-15 | 1995-04-11 | Syntex (U.S.A.) Inc. | Chemotherapeutic maleimides |
| US5559228A (en) | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
| JPH0961647A (ja) | 1995-08-25 | 1997-03-07 | Nippon Telegr & Teleph Corp <Ntt> | 光素子用有機材料 |
| FR2772266B1 (fr) | 1997-12-12 | 2000-02-04 | Oreal | Utilisation d'agent de coloration photochrome dans une composition cosmetique, et composition cosmetique le comprenant |
| ATE284387T1 (de) | 1998-10-08 | 2004-12-15 | Smithkline Beecham Plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2- nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3) |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| DE10042603B4 (de) | 1999-08-31 | 2010-04-29 | Kyocera Corp. | Photochrome Verbindung und ihre Verwendung in optischen Funktionsvorrichtungen |
| AU1189201A (en) | 1999-10-22 | 2001-05-08 | Eli Lilly And Company | Therapeutic compositions including protein kinase c inhibitors |
| US6281356B1 (en) | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
| DE60129222T2 (de) | 2000-05-11 | 2008-03-06 | Consejo Superior de Investigaciónes Científicas | Heterocyclischen inhibitoren von glycogen synthase kinase gsk-3 |
| CA2417277A1 (en) | 2000-07-27 | 2002-02-07 | F. Hoffmann-La Roche Ag | 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3.beta. |
| PT1337527E (pt) * | 2000-11-07 | 2009-12-10 | Novartis Ag | Derivados de indolilmaleimida como inibidores da proteína quinase c |
| JP2002285146A (ja) | 2001-03-27 | 2002-10-03 | Masahiro Irie | フォトクロミック組成物及び線量計 |
| DE60209471D1 (de) | 2001-03-29 | 2006-04-27 | Topo Target As Copenhagen Koeb | Succinimid- und maleimidderivate und ihre verwendung als katalytische inhibitoren der topoisomerase ii |
| BE1014306A6 (fr) | 2001-07-19 | 2003-08-05 | Project 21C | Dispositif de stationnement d'un cycle avec antivol. |
| MXPA04008671A (es) * | 2002-03-08 | 2004-12-06 | Lilly Co Eli | Derivados de pirrol-2,5-diona y su uso como inhibidores de gsk-3. |
| AR039209A1 (es) * | 2002-04-03 | 2005-02-09 | Novartis Ag | Derivados de indolilmaleimida |
-
2003
- 2003-02-13 GB GBGB0303319.8A patent/GB0303319D0/en not_active Ceased
-
2004
- 2004-02-12 ES ES04710393T patent/ES2343115T3/es not_active Expired - Lifetime
- 2004-02-12 US US10/542,175 patent/US7820672B2/en not_active Expired - Fee Related
- 2004-02-12 PT PT04710393T patent/PT1597250E/pt unknown
- 2004-02-12 DE DE602004026415T patent/DE602004026415D1/de not_active Expired - Lifetime
- 2004-02-12 AT AT04710393T patent/ATE463491T1/de active
- 2004-02-12 CA CA002513613A patent/CA2513613A1/en not_active Abandoned
- 2004-02-12 EP EP04710393A patent/EP1597250B8/de not_active Expired - Lifetime
- 2004-02-12 JP JP2005518422A patent/JP2006515004A/ja not_active Ceased
- 2004-02-12 EP EP09004073A patent/EP2075249B1/de not_active Expired - Lifetime
- 2004-02-12 BR BRPI0407512-9A patent/BRPI0407512A/pt not_active IP Right Cessation
- 2004-02-12 ES ES09004073T patent/ES2385071T3/es not_active Expired - Lifetime
- 2004-02-12 AT AT09004073T patent/ATE551335T1/de active
- 2004-02-12 WO PCT/EP2004/001323 patent/WO2004072062A2/en active Application Filing
- 2004-02-12 CN CNB2004800029076A patent/CN100439359C/zh not_active Expired - Fee Related
-
2009
- 2009-07-14 JP JP2009165725A patent/JP2009280592A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2075249B1 (de) | 2012-03-28 |
| EP2075249A2 (de) | 2009-07-01 |
| BRPI0407512A (pt) | 2006-02-14 |
| CN100439359C (zh) | 2008-12-03 |
| EP1597250A2 (de) | 2005-11-23 |
| ES2385071T3 (es) | 2012-07-17 |
| ES2343115T3 (es) | 2010-07-23 |
| US20060058356A1 (en) | 2006-03-16 |
| JP2006515004A (ja) | 2006-05-18 |
| DE602004026415D1 (de) | 2010-05-20 |
| EP1597250B1 (de) | 2010-04-07 |
| ATE463491T1 (de) | 2010-04-15 |
| PT1597250E (pt) | 2010-06-25 |
| CN1742005A (zh) | 2006-03-01 |
| JP2009280592A (ja) | 2009-12-03 |
| EP2075249A3 (de) | 2009-09-02 |
| US7820672B2 (en) | 2010-10-26 |
| WO2004072062A2 (en) | 2004-08-26 |
| CA2513613A1 (en) | 2004-08-26 |
| GB0303319D0 (en) | 2003-03-19 |
| EP1597250B8 (de) | 2010-05-19 |
| WO2004072062A3 (en) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE551335T1 (de) | Indolylmaleimid-derivate | |
| ECSP12006206A (es) | Inhibidores de quinasa p38 basados en heterociclos de 5 miembros. | |
| EA200700757A1 (ru) | Замещённые дипиперидиновые антагонисты ccr2 | |
| MXPA05009595A (es) | Compuestos 7-amino-isoindolilo y sus usos farmaceuticos. | |
| CY1112941T1 (el) | Δικυκλικοι αναστολεις της μεκ | |
| NO20055588D0 (no) | Pyrimidinderivater anvendelige for behandling av sykdommer mediert av CRTH2 | |
| NO20062561L (no) | Kinoliner nyttige for behandling av kardiovaskulaere sykdommer | |
| IS2520B (is) | Nikótínamíð afleiður nytsamlegar sem P38 hindrar | |
| PL1900362T3 (pl) | Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych | |
| BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
| ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
| DE60121345D1 (de) | Alkylierte imidazopyridinderivate | |
| DK1313740T3 (da) | Prodrugs af imidazopyridinderivater | |
| PT1606233E (pt) | Derivados de esteres lipidicos de nucleotidos | |
| ATE473737T1 (de) | Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung |